Drug Search Results
More Filters [+]

Interferon gamma

Alternative Names: interferon gamma, actimmune
Latest Update: 2024-06-26
Latest Update Note: Clinical Trial Update

Product Description

Interferon-gamma (IFN-?) is a pleiotropic molecule with associated antiproliferative, pro-apoptotic and antitumor mechanisms.

Mechanisms of Action: IFNG Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bulgaria | Chile | Denmark | France | Germany | Greece | Hong Kong | Hungary | Ireland | Italy | Japan | Malta | Mexico | Netherlands | New Zealand | Norway | Philippines | Portugal | Russia | Saudi Arabia | Slovenia | Spain | Sweden | Switzerland | Ukraine | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: InterMune
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Interferon gamma

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Candidemia

Phase 1: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

rIFN-Gamma 1b in Candidemia

P2

Active, not recruiting

Candidemia

2025-11-15

STUDY00002655

P1

Recruiting

Asthma

2025-07-01

Recent News Events